Compare Stocks → The Next Step of Their Control Is Here … (From Weiss Ratings) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison CVE:IGX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIGXIntelGenx TechnologiesC$0.58+1.8%C$0.58C$0.17▼C$0.85C$87.32MN/A56,279 shs11,848 shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIGXIntelGenx Technologies0.00%0.00%0.00%0.00%0.00%Protect Yourself While There’s Still Time … (Ad)The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIGXIntelGenx TechnologiesN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIGXIntelGenx TechnologiesN/AN/AN/AN/ASales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIGXIntelGenx TechnologiesC$1.75M49.95C$0.08 per share7.16C$0.05 per share12.89Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIGXIntelGenx TechnologiesN/A-C$0.08N/A∞N/AN/AN/AN/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIGXIntelGenx TechnologiesN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIGXIntelGenx Technologies164.622.772.69OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIGXIntelGenx TechnologiesN/AInsider OwnershipCompanyInsider OwnershipIGXIntelGenx TechnologiesN/AMiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableIGXIntelGenx Technologies48150.55 millionN/ANot OptionableDDDD and IGX HeadlinesSourceHeadlineStocks in play: IntelGenx Corp.ca.finance.yahoo.com - April 8 at 10:41 AMIntelGenx Technologies Corp.: IntelGenx Updates Status of Buprenorphine Buccal Film ANDAfinanznachrichten.de - April 5 at 9:46 AMIntelGenx Launches Preferred Share Regulation A Offeringuk.finance.yahoo.com - February 20 at 12:35 PMNVIDIA partners with Amgen to build generative AI models for drug discoverymsn.com - January 11 at 3:16 PMCHANGES TO BOARD OF DIRECTORS OF GEEKCOfinance.yahoo.com - January 2 at 5:28 PMIntelGenx Technologies Corp.: IntelGenx Announces New Animal Health Partnership; Enters into Development and License Agreements for VetaFilmfinanznachrichten.de - December 18 at 10:07 AMIntelGenx Announces Closing of Previously Announced Subsequent Non-Brokered Private Placement With atai Life Sciences for Aggregate Gross Proceeds of US$750,000finance.yahoo.com - December 5 at 9:13 AMIntelGenx Announces Changes to its Board of Directorsfinance.yahoo.com - December 4 at 8:08 AMIntelGenx Technologies Corp.: IntelGenx Announces Shareholder Approval of Financing Transactionsfinanznachrichten.de - November 29 at 7:00 AMClosing Bell: Intelgenx Technologies Corp up on Monday (IGX)theglobeandmail.com - November 13 at 8:30 PMIntelGenx Technologies Corp.: IntelGenx Reports Third Quarter 2023 Financial Resultsfinanznachrichten.de - November 10 at 7:32 AMClosing Bell: Intelgenx Technologies Corp up on Tuesday (IGX)theglobeandmail.com - November 7 at 10:02 PMIntelGenx to Report Third Quarter 2023 Financial Results on November 9, 2023 – Conference Call to Followfinance.yahoo.com - November 2 at 5:54 PMClosing Bell: Intelgenx Technologies Corp flat on Friday (IGX)theglobeandmail.com - October 21 at 2:23 PMClosing Bell: Intelgenx Technologies Corp down on Thursday (IGX)theglobeandmail.com - October 13 at 1:58 PMClosing Bell: Intelgenx Technologies Corp flat on Thursday (IGX)theglobeandmail.com - October 7 at 1:30 PMIntelGenx Provides Regulatory Update for Xiromed-Partnered Development Candidate, Buprenorphine Buccal Filmfinance.yahoo.com - September 19 at 8:37 AMIntelGenx Technologies (IGXT) Price Target Increased by 8.03% to 0.79msn.com - August 2 at 9:33 AMIntelGenx Technologies Corp.: IntelGenx Announces a Change to its Board of Directorsfinanznachrichten.de - July 25 at 7:58 PMIntelGenx Provides Update on Research Collaboration Evaluating Montelukast VersaFilm® for the Treatment of Parkinson’s Diseasefinance.yahoo.com - July 25 at 8:34 AMIntelGenx Unveils Short-Term Commercial Objectivesfinance.yahoo.com - May 31 at 8:53 AM8-K: IntelGenx Technologies Corp.marketwatch.com - May 11 at 11:46 PMIntelGenx Extends Period to Exercise Certain Warrantsfinance.yahoo.com - April 27 at 7:54 PMIntelGenx Announces Receipt of Complete Response Letter from the FDA for Xiromed-Partnered Buprenorphine Buccal Filmfinance.yahoo.com - April 27 at 9:52 AMMedia Sentiment Over TimeCompany DescriptionsIntelGenx TechnologiesCVE:IGXIntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine. The company's products under development comprise INT0004/2006, an antidepressant; INT0046/2018 for adult use; INT0007/2006 for the treatment of erectile dysfunction; INT0010/2006 for the treatment of neuropathic pain and nausea in cancer patients; INT0027/2011 to treat opioid addition; INT0036/2013 for schizophrenia; and INT0043/2015 to treat Alzheimer's disease; and INT0048/2020 for animal health. It is also developing INT0039/2013, INT0040/2014, INT0052/2020, and INT0053/2020. The company has licensing, development, and supply agreement with Tilray, Inc. and Gensco Pharma; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
